Aakaar Medical Technologies Limited — Investor Meet, 21-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Aakaar Medical Technologies reported a strong H2 FY26 with revenue at 41.63 Cr (+23% YoY) and H2 PAT at 7 Cr. Full-year FY26 revenue hit 67 Cr, with PAT at 6.6 Cr. The company is strategically shifting to a distributor model for improved cash flow and operational efficiency. Key launches like US FDA-approved Letybo and exosome portfolios, plus strong growth in own brands like DRS1512 (80%+ gross margin), are expected to drive 30%+ CAGR. Management aims for a main board listing and sustained profitability, with 93% recurring revenue. Investor sentiment points to disciplined growth.